Webb19 sep. 2024 · We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing … Webb23 maj 2024 · The new approval, announced on May 3, is based on findings from a large clinical trial called KATHERINE that compared T-DM1 with trastuzumab (Herceptin) as …
Patient‐reported outcomes from KATHERINE: A phase 3 study of …
Webb7 dec. 2024 · KATHERINE is an open-label study of 1,486 patients with HER2-positive early-stage breast cancer who received neoadjuvant chemotherapy plus HER2-targeted therapy that included a taxane and trastuzumab, followed by surgery. All patients had residual invasive disease in the breast or axillary lymph nodes. Webb25 mars 2024 · Relying on the positive results in metastatic setting, T-DM1 was tested as adjuvant therapy in patients with residual invasive disease after neoadjuvant chemotherapy for HER2-positive BC. The practice-changing KATHERINE trial showed that adjuvant T-DM1 halved the risk of recurrences in comparison to adjuvant trastuzumab . the mira ballroom
Adjuvant trastuzumab emtansine in HER2-positive breast cancer …
Webb3 sep. 2024 · The EMILIA trial randomized advanced HER2+ BC patients, previously treated with trastuzumab and taxanes, to receive either T-DM1 or the combination of lapatinib plus capecitabine. 110 Final results showed better PFS (median 9.6 months with T-DM1 vs 6.4 months with lapatinib plus capecitabine; HR 0.65; 95% CI, 0.55 to 0.77; P … Webb5 dec. 2024 · The phase III KATHERINE clinical trial compared the use of ado-trastuzumab emtansine (T-DM1; Kadcyla) vs trastuzumab (Herceptin) as adjuvant … Webb5 dec. 2024 · KATHERINE is an open-label study of 1,486 patients with HER2-positive early-stage breast cancer who received neoadjuvant chemotherapy plus HER2-targeted therapy that included a taxane and trastuzumab, followed by surgery. All patients had residual invasive disease in the breast or axillary lymph nodes. the mira foundation inc